The role of PPARγ in the transcriptional control by agonists and antagonists

PPAR Research

Volumn , Issue , 2012, Pages

  Tsukahara, Tamotsu ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,3 CYCLIC PHOSPHATIDIC ACID; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; HUMAN; IC 50; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

EID: 84862301230     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/362361     Document Type: Review

References (101)

1. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
2. Renaud J. P., Moras D., Structural studies on nuclear receptors Cellular and Molecular Life Sciences 2000 57 12 1748 1769
3. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
4. Robinson-Rechavi M., Carpentier A. S., Duffraisse M., Laudet V., How many nuclear hormone receptors are there in the human genome? Trends in Genetics 2001 17 10 554 556 (Pubitemid 32918290)
5. Gulick T., Cresci S., Caira T., Moore D. D., Kelly D. P., The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression Proceedings of the National Academy of Sciences of the United States of America 1994 91 23 11012 11016 (Pubitemid 24349615)
6. Kersten S., Seydoux J., Peters J. M., Gonzalez F. J., Desvergne B., Wahli W., Peroxisome proliferator-activated receptor mediates the adaptive response to fasting Journal of Clinical Investigation 1999 103 11 1489 1498
7. Palmer C. N., Hsu M. H., Griffin K. J., Raucy J. L., Johnson E. F., Peroxisome proliferator activated receptor- expression in human liver Molecular Pharmacology 1998 53 1 14 22 (Pubitemid 28068368)
8. Reilly S. M., Bhargava P., Liu S., Gangl M. R., Gorgun C., Nofsinger R. R., Evans R. M., Qi L., Hu F. B., Lee C. H., Nuclear receptor corepressor SMRT regulates mitochondrial oxidative metabolism and mediates aging-related metabolic deterioration Cell Metabolism 2010 12 6 643 653
9. Ferré P., The biology of peroxisome proliferator-activated receptors: relationship with Lipid metabolism and insulin sensitivity Diabetes 2004 53 Supplement 1 S43 S50
10. Krey G., Keller H., Mahfoudi A., Medin J., Ozato K., Dreyer C., Wahli W., Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid x receptor and activation by fatty acids Journal of Steroid Biochemistry and Molecular Biology 1993 47 16 65 73 (Pubitemid 24040942)
11. Elbrecht A., Chen Y., Cullinan C. A., Hayes N., Leibowitz M. D., Moller D. E., Berger J., Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors 1 and 2 Biochemical and Biophysical Research Communications 1996 224 2 431 437 (Pubitemid 26268204)
12. Way J. M., Harrington W. W., Brown K. K., Gottschalk W. K., Sundseth S. S., Mansfield T. A., Ramachandran R. K., Willson T. M., Kliewer S. A., Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor activation has coordinate effects on gene expression in multiple insulin-sensitive tissues Endocrinology 2001 142 3 1269 1277 (Pubitemid 32202838)
13. Zhang C., Baker D. L., Yasuda S., Makarova N., Balazs L., Johnson L. R., Marathe G. K., McIntyre T. M., Xu Y., Prestwich G. D., Byun H. S., Bittman R., Tigyi G., Lysophosphatidic acid induces neointima formation through PPAR activation Journal of Experimental Medicine 2004 199 6 763 774 (Pubitemid 38375196)
14. Tsukahara T., Tsukahara R., Fujiwara Y., Yue J., Cheng Y., Guo H., Bolen A., Zhang C., Balazs L., Re F., Du G., Frohman M. A., Baker D. L., Parrill A. L., Uchiyama A., Kobayashi T., Murakami-Murofushi K., Tigyi G., Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPAR by cyclic phosphatidic acid Molecular Cell 2010 39 3 421 432
15. Zheng F., Cornacchia F., Schulman I., Banerjee A., Cheng Q. L., Potier M., Rita Plati A., Berho M., Elliot S. J., Li J., Fornoni A., Zang Y. J., Zisman A., Striker L. J., Striker G. E., Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors Diabetes 2004 53 9 2420 2427 (Pubitemid 39145598)
16. Rother E., Brandl R., Baker D. L., Goyal P., Gebhard H., Tigyi G., Siess W., Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques Circulation 2003 108 6 741 747 (Pubitemid 36999261)
17. Oishi-Tanaka Y., Glass C. K., A new role for cyclic phosphatidic acid as a PPAR antagonist Cell Metabolism 2010 12 3 207 208
18. Sharma A. M., Staels B., Review: peroxisome proliferator-activated receptor and adipose tissueUnderstanding obesity-related changes in regulation of lipid and glucose metabolism Journal of Clinical Endocrinology and Metabolism 2007 92 2 386 395
19. Whitehead J. P., Diabetes: new conductors for the peroxisome proliferator-activated receptor (PPAR ) orchestra International Journal of Biochemistry and Cell Biology 2011 43 8 1071 1074
20. Tontonoz P., Hu E., Spiegelman B. M., Stimulation of adipogenesis in fibroblasts by PPAR 2, a lipid-activated transcription factor Cell 1994 79 7 1147 1156
21. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A. M., Saladin R., Najib J., Laville M., Fruchart J. C., Deeb S., Vidal-Puig A., Flier J., Briggs M. R., Staels B., Vidal H., Auwerx J., The organization, promoter analysis, and expression of the human PPAR gene Journal of Biological Chemistry 1997 272 30 18779 18789 (Pubitemid 27318225)
22. MacDougald O. A., Lane M. D., Transcriptional regulation of gene expression during adipocyte differentiation Annual Review of Biochemistry 1995 64 345 373
23. Nagy L., Tontonoz P., Alvarez J. G., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR Cell 1998 93 2 229 240 (Pubitemid 28180856)
24. Huin C., Corriveau L., Bianchi A., Keller J. M., Collet P., Krémarik-Bouillaud P., Domenjoud L., Bécuwe P., Schohn H., Ménard D., Daua M., Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract Journal of Histochemistry and Cytochemistry 2000 48 5 603 611 (Pubitemid 30233184)
25. Cheon C. W., Kim D. H., Kim D. H., Cho Y. H., Kim J. H., Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells World Journal of Gastroenterology 2009 15 3 310 320
26. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M., Differentiation and reversal of malignant changes in colon cancer through PPAR Nature Medicine 1998 4 9 1046 1052 (Pubitemid 28417337)
27. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U T., Baird S. M., Thomazy V. A., Evans R. M., Activators of the nuclear receptor PPAR enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061 (Pubitemid 28417339)
28. Dai Y., Wang W. H., Peroxisome proliferator-activated receptor and colorectal cancer World Journal of Gastrointestinal Oncology 2010 2 3 159 164
29. Camp H. S., Li O., Wise S. C., Hong Y. H., Frankowski C. L., Shen X. Q., Vanbogelen R., Leff T., Differential activation of peroxisome proliferator-activated receptor- by troglitazone and rosiglitazone Diabetes 2000 49 4 539 547 (Pubitemid 30183741)
30. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schtz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R. M., The nuclear receptor super-family: the second decade Cell 1995 83 6 835 839
31. Brivanlou A. H., Darnell J. E. Jr., Signal transduction and the control of gene expression Science 2002 295 5556 813 818 (Pubitemid 34118354)
32. Nolte R. T., Wisely G. B., Westin S., Cobb J. E., Lambert M. H., Kurokawa R., Rosenfeld M. G., Willson T. M., Glass C. K., Milburn M. V., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- Nature 1998 395 6698 137 143 (Pubitemid 28425645)
33. Schupp M., Lazar M. A., Endogenous ligands for nuclear receptors: digging deeper Journal of Biological Chemistry 2010 285 52 40409 40415
34. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR ) Journal of Biological Chemistry 1995 270 22 12953 12956
35. Goldstein B. J., Rosiglitazone International Journal of Clinical Practice 2000 54 5 333 337 (Pubitemid 30386644)
36. Lenhard J. M., Kliewer S. A., Paulik M. A., Plunket K. D., Lehmann J. M., Weiel J. E., Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways Biochemical Pharmacology 1997 54 7 801 808 (Pubitemid 27404681)
37. Wang M., Wise S. C., Leff T., Su T. Z., Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor- Diabetes 1999 48 2 254 260 (Pubitemid 29061095)
38. Lawrence J. M., Reckless J., Pioglitazone International Journal of Clinical Practice 2000 54 9 614 618
39. Gillies P. S., Dunn C. J., Pioglitazone Drugs 2000 60 2 333 343
40. Park S. W., Yi J. H., Miranpuri G., Satriotomo I., Bowen K., Resnick D. K., Vemuganti R., Thiazolidinedione class of peroxisome proliferator-activated receptor agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats Journal of Pharmacology and Experimental Therapeutics 2007 320 3 1002 1012 (Pubitemid 46294061)
41. Peraza M. A., Burdick A. D., Marin H. E., Gonzalez F. J., Peters J. M., The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR) Toxicological Sciences 2006 90 2 269 295
42. Clay C. E., Namen A. M., Atsumi G. I., Trimboli A. J., Fonteh A. N., High K. P., Chilton F. H., Magnitude of peroxisome proliferator-activated receptor- activation is associated with important and seemingly opposite biological responses in breast cancer cells Journal of Investigative Medicine 2001 49 5 413 420 (Pubitemid 32777005)
43. Panigrahy D., Huang S., Kieran M. W., Kaipainen A., PPAR as a therapeutic target for tumor angiogenesis and metastasis Cancer Biology and Therapy 2005 4 7 687 693 (Pubitemid 41351164)
44. Allred C. D., Talbert D. R., Southard R. C., Wang X., Kilgore M. W., PPAR 1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells Journal of Nutrition 2008 138 2 250 256 (Pubitemid 351213635)
45. Capobianco E., White V., Higa R., Martnez N., Jawerbaum A., Effects of natural ligands of PPAR on lipid metabolism in placental tissues from healthy and diabetic rats Molecular Human Reproduction 2008 14 8 491 499
46. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M., 15-deoxy-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR Cell 1995 83 5 803 812 (Pubitemid 3006324)
47. Yu K., Bayona W., Kallen C. B., Harding H. P., Ravera C. P., McMahon G., Brown M., Lazar M. A., Differential activation of peroxisome proliferator-activated receptors by eicosanoids Journal of Biological Chemistry 1995 270 41 23975 23983
48. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation Cell 1995 83 5 813 819 (Pubitemid 3006325)
49. Kobayashi Y., Ueki S., Mahemuti G., Chiba T., Oyamada H., Saito N., Kanda A., Kayaba H., Chihara J., Physiological levels of 15-deoxy-12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor- ligation Journal of Immunology 2005 175 9 5744 5750 (Pubitemid 41508057)
50. Kim E. H., Na H. K., Kim D. H., Park S. A., Kim H. N., Song N. Y., Surh Y. J., 15-Deoxy-12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS Carcinogenesis 2008 29 4 688 695
51. Lee S. J., Kim M. S., Park J. Y., Woo J. S., Kim Y. K., 15-Deoxy-12,14-prostaglandin J2 induces apoptosis via JNK-mediated mitochondrial pathway in osteoblastic cells Toxicology 2008 248 2-3 121 129
52. McIntyre T. M., Pontsler A. V., Silva A. R., St. Hilaire A. A., Xu Y., Hinshaw J. C., Zimmerman G. A., Hama K., Aoki J., Arai H., Prestwich G. D., Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR agonist Proceedings of the National Academy of Sciences of the United States of America 2003 100 1 131 136 (Pubitemid 36078041)
53. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W. J., Allison P., Yuan H., Baker D. L., Li Z., Bittman R., Parrill A., Tigyi G., Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor Journal of Biological Chemistry 2006 281 6 3398 3407 (Pubitemid 43845954)
54. Davies S. S., Pontsler A. V., Marathe G. K., Harrison K. A., Murphy R. C., Hinshaw J. C., Prestwich G. D., Hilaire A. S., Prescott S. M., Zimmerman G. A., McIntyre T. M., Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor ligands and agonists Journal of Biological Chemistry 2001 276 19 16015 16023
55. Li Y., Zhang J., Schopfer F. J., Martynowski D., Garcia-Barrio M. T., Kovach A., Suino-Powell K., Baker P. R. S., Freeman B. A., Chen Y. E., Xu H. E., Molecular recognition of nitrated fatty acids by PPAR Nature Structural and Molecular Biology 2008 15 8 865 867
56. Moolenaar W. H., Jalink K., van Corven E. J., Lysophosphatidic acid: a bioactive phospholipid with growth factor-like properties Reviews of Physiology Biochemistry and Pharmacology 1992 119 47 65
57. Tigyi G., Dyer D. L., Miledi R., Lysophosphatidic acid possesses dual action in cell proliferation Proceedings of the National Academy of Sciences of the United States of America 1994 91 5 1908 1912 (Pubitemid 24080315)
58. Tigyi G., Parrill A. L., Molecular mechanisms of lysophosphatidic acid action Progress in Lipid Research 2003 42 6 498 526 (Pubitemid 37237637)
59. Stapleton C. M., Mashek D. G., Wang S., Nagle C. A., Cline G. W., Thuillier P., Leesnitzer L. M., Li L. O., Stimmel J. B., Shulman G. I., Coleman R. A., Lysophosphatidic acid activates peroxisome proliferator activated receptor- in CHO cells that over-express glycerol 3-phosphate acyltransferase-1 PLoS ONE 2011 6 4
60. Mendel C. M., Mendel D. B., Non-specific binding. The problem, and a solution Biochemical Journal 1985 228 1 269 272
61. Xu H. E., Lambert M. H., Montana V. G., Plunket K. D., Moore L. B., Collins J. L., Oplinger J. A., Kliewer S. A., Gampe R. T., McKee D. D., Moore J. T., Willson T. M., Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 2001 98 24 13919 13924 (Pubitemid 33115999)
62. Staels B., Fruchart J. C., Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 2005 54 8 2460 2470 (Pubitemid 41134276)
63. Racke M. K., Gocke A. R., Muir M., Diab A., Drew P. D., Lovett-Racke A. E., Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis Journal of Nutrition 2006 136 3 700 703 (Pubitemid 43363757)
64. Belvisi M. G., Hele D. J., Peroxisome proliferator-activated receptors as novel targets in lung disease Chest 2008 134 1 152 157 (Pubitemid 352008777)
65. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T., Efficacy of PPAR- agonist pioglitazone in mild Alzheimer disease Neurobiology of Aging 2011 32 9 1626 1633
66. Wright H. M., Clish C. B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C. N., Spiegelman B. M., A synthetic antagonist for the peroxisome proliferator-activated receptor inhibits adipocyte differentiation Journal of Biological Chemistry 2000 275 3 1873 1877 (Pubitemid 30060811)
67. Bishop-Bailey D., Hla T., Warner T. D., Bisphenol A diglycidyl ether (BADGE) is a PPAR agonist in an ECV304 cell line British Journal of Pharmacology 2000 131 4 651 654
68. Nakamuta M., Enjoji M., Uchimura K., Ohta S., Sugimoto R., Kotoh K., Kato M., Irie T., Muta T., Nawata H., Bisphenol A diglycidyl ether (BADGE) suppresses tumor necrosis factor- production as a PPAR agonist in the murine macrophage-like cell line, RAW 264.7 Cell Biology International 2002 26 3 235 241
69. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., Wahli W., A new selective peroxisome proliferator-activated receptor antagonist with antiobesity and antidiabetic activity Molecular Endocrinology 2002 16 11 2628 2644 (Pubitemid 35266080)
70. Camp H. S., Chaudhry A., Leff T., A novel potent antagonist of peroxisome proliferator-activated receptor blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes Endocrinology 2001 142 7 3207 3213 (Pubitemid 32575558)
71. Leesnitzer L. M., Parks D. J., Bledsoe R. K., Cobb J. E., Collins J. L., Consler T. G., Davis R. G., Hull-Ryde E. A., Lenhard J. M., Patel L., Plunket K. D., Shenk J. L., Stimmel J. B., Therapontos C., Willson T. M., Blanchard S. G., Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662 Biochemistry 2002 41 21 6640 6650 (Pubitemid 34547354)
72. Al-Alem L., Southard R. C., Kilgore M. W., Curry T. E., Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPAR independent manner PLoS ONE 2011 6 1
73. Lee G., Elwood F., McNally J., Weiszmann J., Lindstrom M., Amaral K., Nakamura M., Miao S., Cao P., Marc Learned R., Chen J. L., Li Y., T0070907, a selective ligand for peroxisome proliferator-activated receptor, functions as an antagonist of biochemical and cellular activities Journal of Biological Chemistry 2002 277 22 19649 19657 (Pubitemid 34967479)
74. Horlein A. J., Naar A. M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C. K., Rosenfeld M. G., Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor Nature 1995 377 6548 397 404
75. Reginato M. J., Krakow S. L., Bailey S. T., Lazar M. A., Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor Journal of Biological Chemistry 1998 273 4 1855 1858 (Pubitemid 28069225)
76. Vane S. J., Differential inhibition of cyclooxygenase isoforms: an explanation of the action of NSAIDs Journal of Clinical Rheumatology 1998 4 supplement 5 S3 S10
77. Murakami-Murofushi K., Mukai M., Kobayashi S., Kobayashi T., Tigyi G., Murofushi H., A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological functions Annals of the New York Academy of Sciences 2000 905 319 321 (Pubitemid 30255438)
78. Fujiwara Y., Cyclic phosphatidic acida unique bioactive phospholipid Biochimica et Biophysica Acta 2008 1781 9 519 524
79. Murakami-Murofushi K., Uchiyama A., Fujiwara Y., Kobayashi T., Kobayashi S., Mukai M., Murofushi H., Tigyi G., Biological functions of a novel lipid mediator, cyclic phosphatidic acid Biochimica et Biophysica Acta 2002 1582 13 1 7 (Pubitemid 34634105)
80. Bakera D. L., Fujiwara Y., Pigg K. R., Tsukahara R., Kobayashi S., Murofushi H., Uchiyama A., Murakami-Murofushi K., Koh E., Bandle R. W., Byun H. S., Bittman R., Fan D., Murph M., Mills G. B., Tigyi G., Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis Journal of Biological Chemistry 2006 281 32 22786 22793
81. Uchiyama A., Mukai M., Fujiwara Y., Kobayashi S., Kawai N., Murofushi H., Inoue M., Enoki S., Tanaka Y., Niki T., Kobayashi T., Tigyi G., Murakami-Murofushi K., Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid Biochimica et Biophysica Acta 2007 1771 1 103 112 (Pubitemid 46073879)
82. Sugii S., Evans R. M., Epigenetic codes of PPAR in metabolic disease FEBS Letters 2011 585 13 2121 2128
83. Esteller M., Cancer epigenomics: DNA methylomes and histone-modification maps Nature Reviews Genetics 2007 8 4 286 298 (Pubitemid 46439286)
84. Hamilton J. P., Epigenetics: principles and practice Digestive Diseases 2011 29 2 130 135
85. Bird A. P., Wolffe A. P., Methylation-induced repression-belts, braces, and chromatin Cell 1999 99 5 451 454 (Pubitemid 129746827)
86. Musri M. M., Gomis R., Prrizas M., Chromatin and chromatin-modifying proteins in adipogenesis Biochemistry and Cell Biology 2007 85 4 397 410 (Pubitemid 47518035)
87. Fujiki K., Kano F., Shiota K., Murata M., Expression of the peroxisome proliferator activated receptor gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes BMC Biology 2009 7, article 38
88. Green C. D., Han J. D. J., Epigenetic regulation by nuclear receptors Epigenomics 2011 3 1 59 72
89. Grunstein M., Histone acetylation in chromatin structure and transcription Nature 1997 389 6649 349 352 (Pubitemid 27415209)
90. Zhang J., Henagan T. M., Gao Z., Ye J., Inhibition of glyceroneogenesis by histone deacetylase 3 contributes to lipodystrophy in mice with adipose tissue inflammation Endocrinology 2011 152 5 1829 1838
91. Hermanson O., Glass C. K., Rosenfeld M. G., Nuclear receptor coregulators: multiple modes of modification Trends in Endocrinology and Metabolism 2002 13 2 55 60 (Pubitemid 36740447)
92. Baniahmad A., Nuclear hormone receptor co-repressors Journal of Steroid Biochemistry and Molecular Biology 2005 93 25 89 97 (Pubitemid 40602480)
93. Heldring N., Pawson T., McDonnell D., Treuter E., Gustafsson J., Pike A. C., Structural insights into corepressor recognition by antagonist-bound estrogen receptors Journal of Biological Chemistry 2007 282 14 10449 10455 (Pubitemid 47096592)
94. Rosenfeld M. G., Lunyak V. V., Glass C. K., Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response Genes and Development 2006 20 11 1405 1428 (Pubitemid 43830648)
95. Karagianni P., Wong J., HDAC3: taking the SMRT-N-CoRrect road to repression Oncogene 2007 26 37 5439 5449 (Pubitemid 47255926)
96. Li J., Wang J., Wang J., Nawaz Z., Liu J. M., Qin J., Wong J., Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 EMBO Journal 2000 19 16 4342 4350 (Pubitemid 30623745)
97. Perissi V., Rosenfeld M. G., Controlling nuclear receptors: the circular logic of cofactor cycles Nature Reviews Molecular Cell Biology 2005 6 7 542 554 (Pubitemid 40943045)
98. Aranda A., Pascual A., Nuclear hormone receptors and gene expression Physiological Reviews 2001 81 3 1269 1304 (Pubitemid 32606670)
99. Yoshida K., Nishida W., Hayashi K., Ohkawa Y., Ogawa A., Aoki J., Arai H., Sobue K., Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo Circulation 2003 108 14 1746 1752 (Pubitemid 37243665)
100. Tsukahara T., Hanazawa S., Kobayashi T., Iwamoto Y., Murakami-Murofushi K., Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor Prostaglandins and Other Lipid Mediators 2010 93 3-4 126 133
101. Tsukahara T., Hanazawa S., Murakami-Murofushi K., Cyclic phosphatidic acid influences the expression and regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 cells Biochemical and Biophysical Research Communications 2011 404 1 109 114